These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 30171563)
1. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva. Maruyama R; Yokota T Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563 [TBL] [Abstract][Full Text] [Related]
2. Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1 Maruyama R; Nguyen Q; Roshmi RR; Touznik A; Yokota T Nucleic Acid Ther; 2022 Jun; 32(3):185-193. PubMed ID: 35085461 [TBL] [Abstract][Full Text] [Related]
3. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation. Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819 [TBL] [Abstract][Full Text] [Related]
4. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling. Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160 [TBL] [Abstract][Full Text] [Related]
5. Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva. Shi S; Cai J; de Gorter DJ; Sanchez-Duffhues G; Kemaladewi DU; Hoogaars WM; Aartsma-Rus A; 't Hoen PA; ten Dijke P PLoS One; 2013; 8(7):e69096. PubMed ID: 23861958 [TBL] [Abstract][Full Text] [Related]
6. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907 [TBL] [Abstract][Full Text] [Related]
7. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1 Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796 [TBL] [Abstract][Full Text] [Related]
8. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1 Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986 [TBL] [Abstract][Full Text] [Related]
9. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014 [TBL] [Abstract][Full Text] [Related]
10. AAV-Mediated Targeting of the Activin A-ACVR1 Yang YS; Lin C; Ma H; Xie J; Kaplan FS; Gao G; Shim JH Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759764 [TBL] [Abstract][Full Text] [Related]
11. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification. Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634 [TBL] [Abstract][Full Text] [Related]
14. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436 [TBL] [Abstract][Full Text] [Related]
15. A case of Fibrodysplasia Ossificans Progressiva associated with a novel variant of the ACVR1 gene. Cappato S; Traberg R; Gintautiene J; Zara F; Bocciardi R Mol Genet Genomic Med; 2021 Oct; 9(10):e1774. PubMed ID: 34347384 [TBL] [Abstract][Full Text] [Related]
16. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish. Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499 [TBL] [Abstract][Full Text] [Related]
17. Patients with ACVR1 Kou S; De Cunto C; Baujat G; Wentworth KL; Grogan DR; Brown MA; Di Rocco M; Keen R; Al Mukaddam M; le Quan Sang KH; Masharani U; Kaplan FS; Pignolo RJ; Hsiao EC Orphanet J Rare Dis; 2020 Jul; 15(1):193. PubMed ID: 32727600 [TBL] [Abstract][Full Text] [Related]
18. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva. Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611 [TBL] [Abstract][Full Text] [Related]
19. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response. Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089 [TBL] [Abstract][Full Text] [Related]